This research applies communication and behavioural theories to comprehensively assess confidence in and acceptance of HPV vaccines in Japan, Korea, and China amongst people who have not received the vaccine, in order to develop effective digital communication strategies to increase uptake.
The IRIS Academic Research Group was founded by some of the world’s leading researchers and academic institutions and launched in June 2021 at the inaugural Global Vaccine Confidence Summit as part of the UK government’s G7 Presidency.
Overview Human Papillomavirus (HPV) is the fourth biggest cause of mortality amongst women in Brazil according to the Pan American Health Organisation (PAHO) but COVID-19…
Years of lies and rumours about COVID have had a contagion effect, damaging public acceptance of all vaccines, said…
We are delighted to announce that Professor Heidi J.
This event is part of the Speaker Series on Misinformation, co-sponsored by the Shorenstein Center for Media,…
It’s so easy to think “vaccine-derived” means that people contract polio from the vaccine itself.
In this review article, examples of hesitancy regarding the measles–mumps–rubella (MMR), human papillomavirus (HPV), and COVID-19 vaccines are used to explore the multifaceted issues that fuel vaccine hesitancy. Each of these examples is part of a larger, more complex story.
Prof Hannah Fry meets seven unvaccinated people to investigate why around four million adults remain unvaccinated against Covid-19, and to find out…
Japan has one of the highest vaccine hesitancy rates in the world. However, few studies have assessed how mobile messenger apps affect COVID-19 vaccine hesitancy. This study used a cross-sectional survey to assess the impact of text messages from Corowa-kun – a free chatbot – on COVID-19 vaccine hesitancy amongst users.
As founding director of The Vaccine Confidence Project, Professor Heidi Larson knows a few things about building…
There’s been a worrying decline in diphtheria, polio and measles jabs. We should heed the lessons of COVID-19.